SHL Telemedicine Ltd.
SMDCF
Other OTC17.15
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.99
3Y
- -
68.07
5Y
- -
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Erez Nachtomy
- Full Time Employees
- 402
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Ashdar Building Tel Aviv Israel 67891
- IPO Date
- Nov 16, 2016
- Website
- shl-telemedicine.com
- Similar Companies
- Business
- SHL Telemedicine Ltd. develops and markets personal telemedicine solutions focused on remote patient monitoring and medical call center services for chronic disease management, including cardiovascular conditions and congestive heart failure; its core products encompass devices such as the TelePress blood pressure monitor, automatic transmission systems for vital signs like heart rate, systolic and diastolic values, and comprehensive monitoring programs that enable real-time data analysis, compliance tracking, patient education, and intervention alerts to reduce hospitalizations and improve outcomes. The company provides telemedicine services to individuals, healthcare providers, and insurers through proprietary platforms that facilitate daily or symptom-based data transmission from user-friendly devices to centralized centers for physician-guided adjustments. SHL Telemedicine Ltd., founded in 1987 and headquartered at Yigal Alon 90 in Tel Aviv, Israel, operates primarily in Israel and Europe with international reach, targeting health insurers, payers, and patients managing chronic conditions such as CHF. Recent developments include the March 2025 acquisition of the remaining 30% stake in Mediton Medical Centers Chain Ltd. to consolidate ownership following the initial 70% purchase; a November 2025 rights offering and successful capital increase to bolster share capital; delisting of ADRs from Nasdaq in March 2025 to terminate U.S. reporting obligations; appointment of Lior Haalman as CFO in February 2025 and David Arnon as CEO in July 2024; and half-year 2025 results announced in September 2025 alongside plans for further capital raises.